Compare CCTG & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCTG | AZTR |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8M | 1.9M |
| IPO Year | 2022 | 2023 |
| Metric | CCTG | AZTR |
|---|---|---|
| Price | $0.47 | $0.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 36.1K | ★ 20.1M |
| Earning Date | 12-23-2025 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.06 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.08 | $0.10 |
| 52 Week High | $2.61 | $1.40 |
| Indicator | CCTG | AZTR |
|---|---|---|
| Relative Strength Index (RSI) | 46.06 | 69.21 |
| Support Level | $0.45 | $0.25 |
| Resistance Level | $1.13 | $0.36 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 42.33 | 68.60 |
CCSC Technology International Holdings Ltd along with its subsidiaries is involved in the sale, design, and manufacturing of interconnect products, including connectors, cables, and wire harnesses. Its products include customized interconnect products, including connectors, cables, and harnesses that are used for a range of applications in a diversified set of industries, including industrial, automotive, robotics, medical equipment, computer, network and telecommunication, and consumer products. Geographically, the company generates maximum revenue from the sale of its products in Europe and the rest from the Americas, Asia, and Others.
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.